Unidox Solutab - instructions for use. Unidox Solutab - instructions for use Use during pregnancy and breastfeeding
After oral administration, it is quickly and almost completely absorbed from the gastrointestinal tract. Food intake has little effect on the absorption of doxycycline. Widely distributed in tissues and body fluids. Plasma protein binding is 80-95%. T1/2 is 12-22 hours. It is excreted unchanged in the urine (40%), but the main part of the dose is excreted unchanged in the feces due to the secretion of bile.
Overdose
Symptoms: increased adverse reactions caused by liver damage (vomiting, fever, jaundice, azotemia, increased transaminase levels, increased PT).
Treatment: immediately after taking large doses, gastric lavage, drinking plenty of fluids, and, if necessary, inducing vomiting are recommended. Activated carbon and osmotic laxatives are prescribed. Hemodialysis and peritoneal dialysis are not recommended due to low efficiency.
Storage conditions
At a temperature of 15–25 °C.
Keep out of the reach of children.
Interaction with other drugs
Drugs containing metal ions (antacids, drugs containing iron, magnesium, calcium) form inactive chelates with doxycycline, and therefore their simultaneous administration should be avoided.
When used simultaneously with barbiturates, carbamazepine, phenytoin, the concentration of doxycycline in the blood plasma decreases due to the induction of microsomal liver enzymes, which may cause a decrease in its antibacterial effect.
It is necessary to avoid combination with penicillins, cephalosporins, which have a bactericidal effect and are antagonists of bacteriostatic antibiotics (including doxycycline).
The absorption of doxycycline is reduced by cholestyramine and colestipol (keep an interval of at least 3 hours between doses).
Due to the suppression of intestinal microflora, doxycycline reduces the prothrombin index, which requires dose adjustment of indirect anticoagulants.
Taking doxycycline reduces the reliability of contraception and increases the incidence of breakthrough bleeding while taking estrogen-containing oral contraceptives.
The simultaneous use of retinol increases intracranial pressure.
Side effect
From the digestive system: nausea, vomiting, anorexia, abdominal pain, diarrhea, constipation, dysphagia, glossitis, esophagitis, transient increase in blood levels of liver transaminases, alkaline phosphatase, bilirubin.
From the hematopoietic system: neutropenia, thrombocytopenia, hemolytic anemia.
Allergic reactions: skin rash, itching, eosinophilia; rarely - Quincke's edema, photosensitivity.
Other: increased residual nitrogen, candidiasis, intestinal dysbiosis, discoloration of teeth in children.
Compound
doxycycline monohydrate, equivalent to doxycycline 100 mg
Excipients: microcrystalline cellulose - 45 mg, saccharin - 10 mg, hyprolose (low-substituted) - 18.75 mg, hypromellose - 3.75 mg, colloidal silicon dioxide (anhydrous) - 0.625 mg, magnesium stearate - 2 mg, lactose monohydrate - up to 250 mg.
Directions for use and doses
Adults are prescribed 200 mg/day orally or intravenously (drip) on the first day of treatment, and 100-200 mg/day on subsequent days. Frequency of administration (or intravenous infusion) is 1-2 times/day. For children over 8 years of age and weighing more than 50 kg, the daily dose for oral administration or intravenous administration (drip) is 4 mg/kg on the first day of treatment. In the following days - 2-4 mg/kg/day, depending on the severity of the clinical course of the disease. Frequency of administration (or intravenous infusion) is 1-2 times/day. The recommended minimum time for IV infusion of 100 mg doxycycline (at an infusion solution concentration of 0.5 mg/ml) is 1 hour.
Maximum doses: for adults for oral administration - 300 mg/day or 600 mg/day (depending on the etiology of the pathogen); for intravenous administration - 300 mg/day.
Product description
Dispersible tablets are round, biconvex, from light yellow or gray-yellow to brown with inclusions, with an engraving “173” (tablet code) on one side and a scored line on the other.
With caution (Precautions)
special instructions
Use doxycycline with caution in cases of liver dysfunction. In case of impaired renal function, no dose adjustment is required.
To prevent local irritation (esophagitis, gastritis, ulceration of the gastrointestinal tract), it is recommended to take it during the daytime with plenty of liquid, food or milk. Due to the possible development of photosensitivity, it is necessary to limit insolation during treatment and for 4-5 days after it.
Doxycycline is not used in children under 8 years of age, because tetracyclines (including doxycycline) cause long-term discoloration of teeth, enamel hypoplasia and slower longitudinal growth of skeletal bones in this category of patients.
Doxycycline solution for intravenous administration should be used no later than 72 hours after its preparation.
Use during pregnancy and lactation
Doxycycline is contraindicated for use during pregnancy and lactation. Doxycycline crosses the placental barrier. May cause long-term discoloration of teeth, enamel hypoplasia, suppression of fetal skeletal bone growth, and the development of fatty liver.
If necessary, use during lactation should stop breastfeeding.
Release form
Dispersible tablets are round, biconvex, from light yellow or gray-yellow to brown with inclusions, with an engraving “173” (tablet code) on one side and a scored line on the other.
1 tab.
doxycycline monohydrate, expressed as doxycycline
Expiration date from date of manufacture
Indications for use
Infectious and inflammatory diseases caused by microorganisms sensitive to doxycycline, incl. infections of the respiratory and ENT organs; gastrointestinal infections; purulent infections of the skin and soft tissues (including acne); infections of the genitourinary system (including gonorrhea, primary and secondary syphilis); typhus, brucellosis, rickettsiosis, osteomyelitis, trachoma, chlamydia.
Contraindications
Pregnancy, children under 8 years of age (possibility of formation of insoluble complexes with calcium in the bone skeleton, enamel and dentin of teeth), hypersensitivity to tetracyclines, porphyria, severe liver failure, leukopenia, lactation period, myasthenia gravis (for intravenous administration).
pharmachologic effect
Semi-synthetic antibiotic of the tetracycline group with a broad spectrum of action. It has a bacteriostatic effect by suppressing the protein synthesis of pathogens.
Active against aerobic gram-positive bacteria: Staphylococcus spp. (including strains producing penicillinase), Streptococcus spp. (including Streptococcus pneumoniae), Bacillus anthracis, Listeria monocytogenes; anaerobic bacteria: Clostridium spp.
Doxycycline is also active against aerobic gram-negative bacteria: Neisseria gonorrhoeae, Escherichia coli, Shigella spp., Salmonella spp., Enterobacter spp., Klebsiella spp., Bordetella pertussis, as well as against Rickettsia spp., Treponema spp., Mycoplasma spp. and Chlamydia spp.
Pseudomonas aeruginosa, Proteus spp., Serratia spp., and most strains of Bacteroides fragilis are resistant to doxycycline.
Composition and release form of the drug
Dispersible tablets round, biconvex, from light yellow or gray-yellow to brown with inclusions, with an engraving “173” (tablet code) on one side and a line on the other.
Excipients: microcrystalline cellulose - 45 mg, saccharin - 10 mg, hyprolose (low-substituted) - 18.75 mg, hypromellose - 3.75 mg, colloidal silicon dioxide (anhydrous) - 0.625 mg, magnesium stearate - 2 mg, lactose monohydrate - up to 250 mg.
10 pieces. - blisters made of PVC/aluminum foil (1) - cardboard packs.
pharmachologic effect
Semi-synthetic broad-spectrum antibiotic. It has a bacteriostatic effect by suppressing the protein synthesis of pathogens.
Active against aerobic gram-positive bacteria: Staphylococcus spp. (including strains producing penicillinase), Streptococcus spp. (including Streptococcus pneumoniae), Bacillus anthracis, Listeria monocytogenes; anaerobic bacteria: Clostridium spp.
Doxycycline is also active against aerobic gram-negative bacteria: Neisseria gonorrhoeae, Escherichia coli, Shigella spp., Salmonella spp., Enterobacter spp., Klebsiella spp., Bordetella pertussis, as well as against Rickettsia spp., Treponema spp., Mycoplasma spp. and Chlamydia spp.
Pseudomonas aeruginosa, Proteus spp., Serratia spp., and most strains of Bacteroides fragilis are resistant to doxycycline.
Pharmacokinetics
After oral administration, it is quickly and almost completely absorbed from the gastrointestinal tract. Food intake has little effect on the absorption of doxycycline. Widely distributed in tissues and body fluids. Protein binding is 80-95%. T1/2 is 12-22 hours. It is excreted unchanged in the urine (40%), but the main part of the dose is excreted unchanged in the feces due to the secretion of bile.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to doxycycline, incl. infections of the respiratory and ENT organs; gastrointestinal infections; purulent infections of the skin and soft tissues (including acne); infections of the genitourinary system (including gonorrhea, primary and secondary syphilis); typhus, brucellosis, rickettsiosis, osteomyelitis, trachoma, chlamydia.
Contraindications
Pregnancy, children under 8 years of age (possibility of formation of insoluble complexes with calcium in the bone skeleton, enamel and dentin of teeth), hypersensitivity to tetracyclines, porphyria, severe liver failure, leukopenia, lactation period, myasthenia gravis (for intravenous administration).
Dosage
Adults are prescribed 200 mg/day orally or intravenously (drip) on the first day of treatment, and 100-200 mg/day on subsequent days. Frequency of administration (or intravenous infusion) is 1-2 times/day. For children over 8 years of age and weighing more than 50 kg, the daily dose for oral administration or intravenous administration (drip) is 4 mg/kg on the first day of treatment. In the following days - 2-4 mg/kg/day, depending on the severity of the clinical course of the disease. Frequency of administration (or intravenous infusion) is 1-2 times/day. The recommended minimum time for IV infusion of 100 mg doxycycline (at an infusion solution concentration of 0.5 mg/ml) is 1 hour.
Maximum doses: for adults for oral administration - 300 mg/day or 600 mg/day (depending on the etiology of the pathogen); for intravenous administration - 300 mg/day.
Side effects
From the digestive system: nausea, vomiting, anorexia, diarrhea, constipation, dysphagia, glossitis, esophagitis, transient increase in blood levels of liver transaminases, alkaline phosphatase, bilirubin.
From the hematopoietic system: neutropenia, thrombocytopenia, hemolytic anemia.
Allergic reactions: skin rash, itching, eosinophilia; rarely - Quincke's edema, photosensitivity.
Others: increase in residual nitrogen, candidiasis, intestinal dysbiosis, discoloration of teeth in children.
Drug interactions
Drugs containing metal ions (drugs containing iron, magnesium, calcium) form inactive chelates with doxycycline, and therefore their simultaneous administration should be avoided.
When used simultaneously with barbiturates and phenytoin, the concentration of doxycycline in the blood plasma decreases due to the induction of microsomal liver enzymes, which may cause a decrease in its antibacterial effect.
It is necessary to avoid combination with penicillins, cephalosporins, which have a bactericidal effect and are antagonists of bacteriostatic antibiotics (including doxycycline).
The absorption of doxycycline is reduced by cholestyramine and colestipol (keep an interval of at least 3 hours between doses).
Due to the suppression of intestinal microflora, doxycycline reduces the prothrombin index, which requires dose adjustment of indirect drugs.
Taking doxycycline reduces the reliability of contraception and increases the incidence of breakthrough bleeding while taking estrogen-containing oral contraceptives.
The simultaneous use of retinol increases intracranial pressure.
special instructions
Use doxycycline with caution in cases of liver dysfunction. In case of impaired renal function, no dose adjustment is required.
To prevent local irritation (esophagitis, gastritis, ulceration of the gastrointestinal tract), it is recommended to take it during the daytime with plenty of liquid, food or milk. Due to the possible development of photosensitivity, it is necessary to limit insolation during treatment and for 4-5 days after it.
Doxycycline solution for intravenous administration should be used no later than 72 hours after its preparation.
Pregnancy and lactation
Doxycycline is contraindicated for use during pregnancy and lactation. Doxycycline crosses the placental barrier. May cause long-term discoloration of teeth, enamel hypoplasia, suppression of fetal skeletal bone growth, and the development of fatty liver.
If necessary, use during lactation should stop breastfeeding.
Use in childhood
Doxycycline is not used in children under 8 years of age, because tetracyclines (including doxycycline) cause long-term discoloration of teeth, enamel hypoplasia and slower longitudinal growth of skeletal bones in this category of patients.
For impaired renal function
In case of impaired renal function, no dose adjustment is required.
For liver dysfunction
Contraindicated in severe liver failure. Use doxycycline with caution in cases of liver dysfunction.
Composition and release form
10 pcs in blister; 1 blister in a box.
Description of the dosage form
Round, biconvex tablets from light yellow to gray-yellow in color with “173” (tablet code) engraved on one side and a scored line on the other.
Characteristic
Broad-spectrum antibiotic from the tetracycline group.
pharmachologic effect
pharmachologic effect- bacteriostatic, antibacterial.Suppresses protein synthesis in the microbial cell, disrupting the connection of transport RNAs of the ribosomal membrane.
Pharmacodynamics
Broad-spectrum antibiotic from the tetracycline group. It acts bacteriostatically, suppresses protein synthesis in the microbial cell by interacting with the 30S ribosomal subunit. Active against many gram-positive and gram-negative microorganisms: Streptococcus spp., Treponema spp., Staphylococcus spp., Klebsiella spp., Enterobacter spp.(including E. aerugenes), Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, Listeria monocytogenes, Rickettsia spp., Typhus exanthematicus, Escherichia coli, Shigella spp., Campylobacter fetus, Vibrio cholerae, Yersinia spp. .(including Yersinia pestis), Brucella spp., Francisella tularensis, Bacillus anthracis, Bartonella bacilliformis, Pasteurella multocida, Borrelia recurrentis, Clostridium spp.(except Clostridium difficile), Actinomyces spp., Fusobacterium fusiforme, Calymmatobacterium granulomatis, Propionibacterium acnes, some protozoa (Entamoeba spp., Plasmodium falciparum).
Typically does not affect Acinetobacter spp., Proteus spp., Pseudomonas spp., Serratia spp., Providencia spp., Enterococcus spp.
The possibility of acquired resistance to doxycycline in a number of pathogens, which is often cross-linked within a group, should be taken into account (i.e., strains resistant to doxycycline will simultaneously be resistant to the entire group of tetracyclines).
Pharmacokinetics
Suction
Absorption is fast and high (about 100%). Food intake has little effect on the absorption of the drug.
Cmax of doxycycline in blood plasma (2.6-3 μg/ml) is achieved 2 hours after taking 200 mg; after 24 hours, the concentration of the active substance in blood plasma decreases to 1.5 μg/ml.
After taking 200 mg on the first day of treatment and 100 mg/day on subsequent days, the plasma concentration of doxycycline is 1.5-3 mcg/ml.
Distribution
Doxycycline binds reversibly to plasma proteins (80-90%), penetrates well into organs and tissues, poorly into the cerebrospinal fluid (10-20% of the level in blood plasma), however, the concentration of doxycycline in the cerebrospinal fluid increases with inflammation spinal membrane.
Volume of distribution - 1.58 l/kg. 30-45 minutes after oral administration, doxycycline is found in therapeutic concentrations in the liver, kidneys, lungs, spleen, bones, teeth, prostate gland, eye tissue, pleural and ascitic fluids, bile, synovial exudate, exudate of the maxillary and frontal sinuses, in gingival sulcus fluids.
With normal liver function, the level of the drug in bile is 5-10 times higher than in plasma.
In saliva, 5-27% of the concentration of doxycycline in blood plasma is determined.
Doxycycline crosses the placental barrier and is secreted into breast milk in small quantities.
Accumulates in dentin and bone tissue.
Metabolism
A small portion of doxycycline is metabolized.
Removal
T1/2 after a single oral dose is 16-18 hours, after repeated doses - 22-23 hours.
Approximately 40% of the drug taken is excreted by the kidneys and 20-40% is excreted through the intestines in the form of inactive forms (chelates).
Pharmacokinetics in special clinical situations
The half-life of the drug in patients with impaired renal function does not change, because its excretion through the intestines increases.
Hemodialysis and peritoneal dialysis do not affect the concentration of doxycycline in blood plasma.
Indications of the drug Unidox Solutab ®
Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:
respiratory tract infections, incl. pharyngitis, acute bronchitis, exacerbation of COPD, tracheitis, bronchopneumonia, lobar pneumonia, community-acquired pneumonia, lung abscess, pleural empyema;
infections of ENT organs, incl. otitis media, sinusitis, tonsillitis;
infections of the genitourinary system (cystitis, pyelonephritis, bacterial prostatitis, urethritis, urethrocystitis, urogenital mycoplasmosis, acute orchiepididymitis; endometritis, endocervicitis and salpingoophoritis as part of combination therapy), incl. sexually transmitted infections (urogenital chlamydia, syphilis in patients with penicillin intolerance, uncomplicated gonorrhea (as an alternative therapy), granuloma inguinale, lymphogranuloma venereum);
infections of the gastrointestinal tract and biliary tract (cholera, yersiniosis, cholecystitis, cholangitis, gastroenterocolitis, bacillary and amoebic dysentery, travelers' diarrhea);
infections of the skin and soft tissues (including wound infections after animal bites), severe acne (as part of combination therapy);
other diseases (yaws, legionellosis, chlamydia of various localizations (including prostatitis and proctitis), rickettsiosis, Q fever, Rocky Mountain spotted fever, typhus (including typhus, tick-borne relapsing), Lyme disease (I stage. — erythema migrans), tularemia, plague, actinomycosis, malaria; infectious eye diseases (as part of combination therapy - trachoma); leptospirosis, psittacosis, ornithosis, anthrax (including pulmonary form), bartonellosis, granulocytic ehrlichiosis; whooping cough, brucellosis, osteomyelitis; sepsis, subacute septic endocarditis, peritonitis);
prevention of postoperative purulent complications;
prevention of malaria caused by Plasmodium falciparum for short-term travel (less than 4 months) to areas where strains resistant to chloroquine and/or pyrimethamine-sulfadoxine are common.
Contraindications
hypersensitivity to tetracyclines;
severe impairment of liver and/or kidney function;
porphyria;
pregnancy;
breast-feeding;
age up to 8 years.
Use during pregnancy and breastfeeding
Contraindicated during pregnancy. Breastfeeding should be stopped during treatment.
Side effects
From the gastrointestinal tract: anorexia, nausea, vomiting, dysphagia, diarrhea; enterocolitis, pseudomembranous colitis.
Dermatological and allergic reactions: urticaria, photosensitivity, angioedema, anaphylactic reactions, exacerbation of systemic lupus erythematosus, maculopapular and erythematous rash, pericarditis, exfoliative dermatitis.
From the liver: liver damage during long-term use or in patients with renal or hepatic impairment.
From the kidneys: increase in residual urea nitrogen (due to the anti-anabolic effect).
From the hematopoietic system: hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia, decreased prothrombin activity.
From the nervous system: benign increase in intracranial pressure (anorexia, vomiting, headache, papilledema), vestibular disorders (dizziness or unsteadiness).
From the thyroid gland: In patients receiving long-term doxycycline, reversible dark brown discoloration of the thyroid tissue is possible.
For teeth and bones: doxycycline slows down osteogenesis, disrupts the normal development of teeth in children (the color of teeth irreversibly changes, enamel hypoplasia develops).
Other: candidiasis (stomatitis, glossitis, proctitis, vaginitis) as a manifestation of superinfection.
Interaction
Due to the suppression of intestinal microflora by doxycycline, the prothrombin index decreases, which requires dose adjustment of indirect anticoagulants.
When doxycycline is combined with bactericidal antibiotics that interfere with cell wall synthesis (penicillins, cephalosporins), the effectiveness of the latter is reduced.
Doxycycline reduces the reliability of contraception and increases the frequency of acyclic bleeding when taking estrogen-containing hormonal contraceptives.
Ethanol, barbiturates, rifampicin, carbamazepine, phenytoin and other stimulants of microsomal oxidation, accelerating the metabolism of doxycycline, reduce its concentration in the blood plasma.
The simultaneous use of doxycycline and retinol increases intracranial pressure.
Directions for use and doses
Inside, During meals, the tablet can be swallowed whole, divided into parts or chewed, washed down with a glass of water, or diluted in a small amount of water (about 20 ml).
Usually the duration of treatment is 5-10 days.
Adults and children over 8 years of age weighing more than 50 kg - 200 mg in 1-2 doses on the first day of treatment, then 100 mg daily. In cases of severe infections - at a dose of 200 mg daily throughout treatment.
For children 8-12 years old weighing less than 50 kg, the average daily dose is 4 mg/kg on the first day, then 2 mg/kg per day (in 1-2 doses). In cases of severe infections - at a dose of 4 mg/kg daily throughout treatment.
Features of dosing for certain diseases
For an infection caused by S.pyogenes, Unidox Solutab ® is taken for at least 10 days.
For uncomplicated gonorrhea (except for anorectal infections in men): adults - 100 mg 2 times a day until complete cure (on average within 7 days), or 600 mg - 300 mg in 2 doses are prescribed for one day (second taken 1 hour after the first).
For primary syphilis - 100 mg 2 times a day for 14 days, for secondary syphilis - 100 mg 2 times a day for 28 days.
For uncomplicated urogenital infections caused by Chlamydia trachomatis, cervicitis, non-gonococcal urethritis caused by Ureaplasma urealyticum,- 100 mg 2 times a day for 7 days.
For acne - 100 mg/day; course of treatment - 6-12 weeks.
Malaria (prevention) - 100 mg 1 time per day 1-2 days before the trip, then daily during the trip and for 4 weeks after returning; children over 8 years old - 2 mg/kg 1 time per day.
Travelers' diarrhea (prevention) - 200 mg on the first day of the trip in 1 or 2 doses, then 100 mg 1 time per day during the entire stay in the region (no more than 3 weeks).
Treatment of leptospirosis - 100 mg orally 2 times a day for 7 days; prevention of leptospirosis - 200 mg once a week during your stay in a disadvantaged area and 200 mg at the end of the trip.
To prevent infections during medical abortion - 100 mg 1 hour before and 200 mg after the intervention.
Maximum daily doses for adults are up to 300 mg/day or up to 600 mg/day for 5 days for severe gonococcal infections. For children over 8 years old weighing more than 50 kg - up to 200 mg, for children 8-12 years old weighing less than 50 kg - 4 mg/kg daily throughout treatment.
In the presence of renal (Cl creatinine<60 мл/мин) и/или печеночной недостаточности требуется снижение суточной дозы доксициклина, поскольку при этом происходит постепенное накопление его в организме (риск гепатотоксического действия).
Overdose
Symptoms: increased adverse reactions caused by liver damage (vomiting, fever, jaundice, azotemia, increased transaminase levels, increased PT).
Treatment: Immediately after taking large doses, gastric lavage, drinking plenty of fluids, and, if necessary, inducing vomiting are recommended. Activated carbon and osmotic laxatives are prescribed. Hemodialysis and peritoneal dialysis are not recommended due to low efficiency.
special instructions
There is a possibility of cross-resistance and hypersensitivity to other tetracycline drugs.
Tetracyclines may increase PT; the use of tetracyclines in patients with coagulopathies should be carefully monitored.
The anti-anabolic effect of tetracyclines can lead to an increase in the level of residual urea nitrogen in the blood. As a rule, this is not significant for patients with normal renal function. However, in patients with renal failure, an increase in azotemia may occur. The use of tetracyclines in patients with impaired renal function requires medical supervision.
With long-term use of the drug, periodic monitoring of laboratory blood parameters, liver and kidney function is required.
Due to the possible development of photodermatitis, it is necessary to limit insolation during treatment and for 4-5 days after it.
Long-term use of the drug can cause dysbacteriosis and, as a result, the development of hypovitaminosis (especially B vitamins).
To prevent dyspeptic symptoms, it is recommended to take the drug with meals.
The specific effects on the ability to drive a car and operate machinery have not been studied.
Storage conditions for the drug Unidox Solutab ®
At a temperature not exceeding 25 °C.Keep out of the reach of children.
Shelf life of Unidox Solutab ®
5 years.Do not use after the expiration date stated on the package.
Synonyms of nosological groups
| Category ICD-10 | Synonyms of diseases according to ICD-10 |
|---|---|
| A49.3 Mycoplasma infection, unspecified | Pulmonary infection caused by mycoplasma |
| Mycoplasma infection | |
| Mycoplasma infections | |
| Mycoplasma meningoencephalitis | |
| Mycoplasmosis | |
| Urogenital infection caused by mycoplasma | |
| Urogenital mycoplasmosis | |
| A53.9 Syphilis, unspecified | Syphilis |
| Tertiary syphilis | |
| A54 Gonococcal infection | Gonococcal infections |
| Disseminated gonococcal infection | |
| Disseminated gonorrheal infection | |
| A55 Chlamydial lymphogranuloma (venereal) | Granuloma venereum |
| Lymphogranuloma venereum | |
| Venereal lymphopathy | |
| Lymphogranulomatosis venereum | |
| Lymphogranuloma inguinal | |
| Chlamydial lymphogranuloma | |
| Nicolas-Favre disease | |
| Inguinal lymphogranuloma | |
| Inguinal lymphogranuloma (inguinal ulceration, inguinal lymphogranulomatosis) | |
| Subacute inguinal purulent microporoadenitis | |
| Chlamydial lymphogranuloma | |
| Fourth venereal disease | |
| A69.2 Lyme disease | Lyme Arthritis |
| Backyard disease | |
| Borreliosis | |
| Lyme borreliosis | |
| Tick-borne borreliosis | |
| Lyme borreliosis | |
| Lyme disease | |
| A70 Chlamydia psittaci infection | Bird lovers disease |
| Poultry farmers disease | |
| Psittacosis | |
| Psittacosis | |
| A75 Typhus | Bangalore |
| Louse-borne typhus | |
| Mouse typhus | |
| Tabardillo | |
| Typhus | |
| Toulon typhus | |
| H60 Otitis externa | ENT infections |
| Infections of the external auditory canal | |
| Outer ear infections | |
| Acute catarrhal inflammation of the external auditory canal | |
| H66 Suppurative and unspecified otitis media | Bacterial ear infections |
| Inflammation of the middle ear | |
| ENT infections | |
| Infectious and inflammatory diseases of the ear | |
| Infectious diseases of the ENT organs with severe pain syndrome | |
| Ear infection | |
| Infectious otitis media | |
| Persistent inflammation of the middle ear in children | |
| Ear pain due to otitis media | |
| H70 Mastoiditis and related conditions | Mastoiditis |
| J01 Acute sinusitis | Inflammation of the paranasal sinuses |
| Inflammatory diseases of the paranasal sinuses | |
| Purulent-inflammatory processes of the paranasal sinuses | |
| Infectious and inflammatory disease of ENT organs | |
| Sinus infection | |
| Combined sinusitis | |
| Exacerbation of sinusitis | |
| Acute inflammation of the paranasal sinuses | |
| Acute bacterial sinusitis | |
| Acute sinusitis in adults | |
| Subacute sinusitis | |
| Acute sinusitis | |
| Sinusitis | |
| J02.9 Acute pharyngitis, unspecified | Purulent pharyngitis |
| Lymphonodular pharyngitis | |
| Acute nasopharyngitis | |
| J03.9 Acute tonsillitis, unspecified (angina agranulocytic) | Angina |
| Sore throat, alimentary-hemorrhagic | |
| Sore throat secondary | |
| Primary tonsillitis | |
| Sore throat follicular | |
| Sore throats | |
| Bacterial tonsillitis | |
| Throat infections | |
| Catarrhal sore throat | |
| Lacunar tonsillitis | |
| Acute sore throat | |
| Acute tonsillitis | |
| Tonsillitis | |
| Acute tonsillitis | |
| Tonsillar tonsillitis | |
| Follicular tonsillitis | |
| Follicular tonsillitis | |
| J04 Acute laryngitis and tracheitis | Infectious and inflammatory disease of ENT organs |
| Laryngitis | |
| Laryngitis acute | |
| Acute tracheitis | |
| Pharyngolaryngitis | |
| J06 Acute upper respiratory tract infections of multiple and unspecified localization | Bacterial infections of the upper respiratory tract |
| Pain due to colds | |
| Pain in infectious and inflammatory diseases of the upper respiratory tract | |
| Inflammatory disease of the upper respiratory tract | |
| Inflammatory diseases of the upper respiratory tract | |
| Inflammatory diseases of the upper respiratory tract with difficult to separate sputum | |
| Secondary infections with influenza | |
| Secondary infections due to colds | |
| Influenza conditions | |
| Upper respiratory tract infections | |
| Upper respiratory tract infections | |
| Respiratory tract infections | |
| ENT infections | |
| Infectious and inflammatory diseases of the upper respiratory tract | |
| Infectious and inflammatory diseases of the upper respiratory tract and ENT organs | |
| Infectious and inflammatory diseases of the upper respiratory tract in adults and children | |
| Infectious and inflammatory diseases of the upper respiratory tract | |
| Respiratory tract infection | |
| Qatar of the upper respiratory tract | |
| Catarrhal inflammation of the upper respiratory tract | |
| Catarrhal disease of the upper respiratory tract | |
| Catarrhal phenomena from the upper respiratory tract | |
| Cough in diseases of the upper respiratory tract | |
| Cough with a cold | |
| Fever due to influenza | |
| ARVI | |
| acute respiratory infections | |
| Acute respiratory infection with symptoms of rhinitis | |
| Acute respiratory infection | |
| Acute infectious-inflammatory disease of the upper respiratory tract | |
| Acute cold | |
| Acute respiratory disease | |
| Acute respiratory disease of influenza nature | |
| Sore throat or nose | |
| Cold | |
| Colds | |
| Colds | |
| Respiratory infection | |
| Respiratory diseases | |
| Respiratory infections | |
| Recurrent respiratory tract infections | |
| Seasonal colds | |
| Seasonal colds | |
| Frequent colds and viral diseases | |
| J22 Acute respiratory infection of the lower respiratory tract, unspecified | Bacterial respiratory disease |
| Bacterial lower respiratory tract infections | |
| Bacterial respiratory infections | |
| Viral respiratory disease | |
| Viral respiratory tract infections | |
| Inflammatory diseases of the respiratory tract | |
| Difficulty secreting sputum in acute and chronic respiratory diseases | |
| Respiratory tract infections | |
| Respiratory and lung infections | |
| Lower respiratory tract infections | |
| Lower respiratory tract infections | |
| Infectious inflammation of the respiratory tract | |
| Infectious diseases of the respiratory tract | |
| Infectious lung diseases | |
| Infectious diseases of the respiratory system | |
| Respiratory tract infection | |
| Cough with a cold | |
| Pulmonary infection | |
| Acute respiratory tract infection | |
| Acute respiratory viral infection | |
| Acute inflammatory disease of the respiratory tract | |
| Acute respiratory tract disease | |
| Respiratory infection | |
| Respiratory viral infections | |
| Respiratory syncytial virus infection in young children | |
| Respiratory diseases | |
| Respiratory infections | |
| J31 Chronic rhinitis, nasopharyngitis and pharyngitis | |
| Inflammation of the nasal mucosa | |
| Infectious and inflammatory diseases of the ENT organs | |
| Year-round rhinitis | |
| Ozena | |
| Sore throat or nose | |
| Hyperplastic rhinitis | |
| Chronic rhinitis | |
| Pharyngoesophagitis | |
| Chronic bacterial rhinitis | |
| J32 Chronic sinusitis | Allergic rhinosinusopathy |
| Purulent sinusitis | |
| Catarrhal inflammation of the nasopharyngeal region | |
| Catarrhal inflammation of the paranasal sinuses | |
| Exacerbation of sinusitis | |
| Chronic sinusitis | |
| J35.0 Chronic tonsillitis | Chronic sore throat |
| Inflammatory diseases of the tonsils | |
| Chronic tonsillitis | |
| Tonsillar tonsillitis | |
| Chronic hypertrophic tonsillitis | |
| J37 Chronic laryngitis and laryngotracheitis | Infectious and inflammatory disease of ENT organs |
| Infectious and inflammatory diseases of the ENT organs | |
| K62.8.1* Proctitis | Anusitis |
| Atrophic proctitis | |
| L08.9 Local infection of skin and subcutaneous tissue, unspecified | Soft tissue abscess |
| Bacterial or fungal skin infection | |
| Bacterial skin infections | |
| Bacterial soft tissue infections | |
| Bacterial skin infections | |
| Bacterial skin lesions | |
| Viral skin infection | |
| Viral skin infections | |
| Fiber inflammation | |
| Inflammation of the skin at injection sites | |
| Inflammatory skin diseases | |
| Pustular skin disease | |
| Pustular skin diseases | |
| Purulent-inflammatory disease of the skin and soft tissues | |
| Purulent-inflammatory skin diseases | |
| Purulent-inflammatory diseases of the skin and its appendages | |
| Purulent-inflammatory diseases of soft tissues | |
| Purulent skin infections | |
| Purulent soft tissue infections | |
| Skin infections | |
| Infections of the skin and skin structures | |
| Skin infection | |
| Infectious skin diseases | |
| Skin infection | |
| Infection of the skin and its appendages | |
| Infection of the skin and subcutaneous structures | |
| Infection of the skin and mucous membranes | |
| Skin infection | |
| Skin bacterial infections | |
| Necrotizing subcutaneous infections | |
| Uncomplicated skin infections | |
| Uncomplicated soft tissue infections | |
| Superficial skin erosion with secondary infection | |
| Umbilical infection | |
| Mixed skin infections | |
| Specific infectious processes in the skin | |
| Superinfection of the skin | |
| L70 Acne | Acne nodulocystica |
| Acne | |
| Comedones | |
| Acne treatment | |
| Papular-pustular acne | |
| Papulopustular acne | |
| Papulopustular acne | |
| Pimples | |
| Acne | |
| Acne | |
| Acne | |
| Nodular cystic acne | |
| Nodular cystic acne | |
| M60.0 Infectious myositis | Muscle abscess |
| Soft tissue infections | |
| Infectious myositis | |
| Pyomyositis | |
| Specific infectious processes in soft tissues | |
| M65 Synovitis and tenosynovitis | Inflammatory soft tissue disease |
| Nonspecific tenosynovitis | |
| Acute tenosynovitis | |
| Edema syndrome in muscular-articular diseases | |
| Tenosynovitis | |
| Tenosynovitis (tenovaginitis) | |
| Tenosynovitis | |
| Tenosynovitis (tenosynovitis) | |
| Tenosynovitis | |
| M65.0 Tendon sheath abscess | Soft tissue infections |
| M71.0 Abscess of bursa | Soft tissue infections |
| M71.1 Other infectious bursitis | Bacterial bursitis |
| Infectious bursitis | |
| Soft tissue infections | |
| N30 Cystitis | Exacerbation of chronic cystitis |
| Acute bacterial cystitis | |
| Recurrent cystitis | |
| Urethrocystitis | |
| Fibrous cystitis | |
| Cystopyelitis | |
| N34 Urethritis and urethral syndrome | Bacterial nonspecific urethritis |
| Bacterial urethritis | |
| Bougienage of the urethra | |
| Gonococcal urethritis | |
| Gonorrheal urethritis | |
| Urethral infection | |
| Non-gonococcal urethritis | |
| Non-gonorrheal urethritis | |
| Acute gonococcal urethritis | |
| Acute gonorrheal urethritis | |
| Acute urethritis | |
| Urethral lesion | |
| Urethritis | |
| Urethrocystitis | |
| N39.0 Urinary tract infection without established location | Asymptomatic bacteriuria |
| Bacterial urinary tract infections | |
| Bacterial urinary tract infections | |
| Bacteriuria | |
| Bacteriuria asymptomatic | |
| Chronic latent bacteriuria | |
| Asymptomatic bacteriuria | |
| Asymptomatic massive bacteriuria | |
| Inflammatory disease of the urinary tract | |
| Inflammatory disease of the genitourinary tract | |
| Inflammatory diseases of the bladder and urinary tract | |
| Inflammatory diseases of the urinary system | |
| Inflammatory diseases of the urinary tract | |
| Inflammatory diseases of the urogenital system | |
| Fungal diseases of the urogenital tract | |
| Fungal infections of the urinary tract | |
| Urinary tract infections | |
| Urinary tract infections | |
| Urinary tract infections | |
| Urinary tract infections | |
| Urinary tract infections | |
| Urinary tract infections caused by enterococci or mixed flora | |
| Uncomplicated genitourinary tract infections | |
| Complicated urinary tract infections | |
| Infections of the genitourinary system | |
| Urogenital infections | |
| Urinary tract infections | |
| Urinary tract infection | |
| Urinary tract infection | |
| Urinary tract infection | |
| Urinary tract infection | |
| Urinary tract infection | |
| Urogenital tract infection | |
| Uncomplicated urinary tract infections | |
| Uncomplicated urinary tract infections | |
| Uncomplicated genitourinary tract infections | |
| Exacerbation of chronic urinary tract infection | |
| Retrograde kidney infection | |
| Recurrent urinary tract infections | |
| Recurrent urinary tract infections | |
| Recurrent urinary tract infections | |
| Mixed urethral infections | |
| Urogenital infection | |
| Urogenital infectious and inflammatory disease | |
| Urogenital mycoplasmosis | |
| Urological disease of infectious etiology | |
| Chronic urinary tract infection | |
| Chronic urinary tract infections | |
| Chronic infectious diseases of the urinary system | |
| N41 Inflammatory diseases of the prostate gland | Prostate disease |
| Genital infection | |
| Prostatitis | |
| Chronic nonspecific prostatitis | |
| N49 Inflammatory diseases of the male genital organs, not elsewhere classified | |
| Bacterial infections of the genitourinary system | |
| Genital infections in men | |
| Urogenital infections | |
| Infectious lesions of the male genital tract | |
| Chronic inflammatory diseases of the pelvic organs | |
| N71 Inflammatory diseases of the uterus, except the cervix | Intrauterine infections |
| Inflammatory diseases of the female genitalia | |
| Inflammatory diseases of the female genital organs | |
| Genital infection | |
| Chronic endomyometritis | |
| Chronic inflammatory disease of the uterus | |
| Endometritis | |
| Endomyometritis | |
| N73.9 Inflammatory diseases of the female pelvic organs, unspecified | Abscess of the pelvic organs |
| Bacterial diseases of the urogenital tract | |
| Bacterial infections of the genitourinary system | |
| Bacterial infections of the pelvic organs | |
| Intrapelvic infections | |
| Inflammation in the area of the cervix | |
| Pelvic inflammatory disease | |
| Pelvic inflammatory disease | |
| Inflammatory gynecological diseases | |
| Inflammatory diseases of the female pelvic organs | |
| Inflammatory diseases of the pelvic organs | |
| Inflammatory diseases of the pelvic organs | |
| Inflammatory infections in the pelvic area | |
| Inflammatory processes in the pelvis | |
| Gynecological infection | |
| Gynecological infections | |
| Gynecological infectious diseases | |
| Purulent-inflammatory diseases of the pelvic organs | |
| Infections of female genital organs | |
| Infections of the pelvic organs in women | |
| Pelvic infections | |
| Infections of the urogenital tract | |
| Infectious diseases of the reproductive system | |
| Infectious diseases of the genital organs | |
| Infection of female genital organs | |
| Metritis | |
| Acute infection of the female genital organs | |
| Acute inflammatory disease of the pelvic organs | |
| Pelvic infection | |
| Tuboovarian inflammation | |
| Chlamydial gynecological infections | |
| Chronic inflammatory diseases of the pelvic organs | |
| Chronic inflammatory diseases of the appendages | |
| Chronic infections of the female genital organs | |
| N74.2 Inflammatory diseases of the female pelvic organs caused by syphilis (A51.4+, A52.7+) | Syphilis |
| N74.3 Gonococcal inflammatory diseases of the female pelvic organs (A54.2+) | Gonorrheal diseases |
| Gonorrhea | |
| Gonococcal urethritis |
Dispersible tablets round, biconvex, from light yellow to gray-yellow in color, with a mark on one side and an engraving “173” (tablet code) on the other.
Excipients: microcrystalline cellulose, saccharin, hyprolose (low-substituted), hypromellose, colloidal silicon dioxide (anhydrous), magnesium stearate, lactose monohydrate.
10 pieces. - blisters (1) - cardboard packs.
Clinical and pharmacological group
Antibiotic of the tetracycline grouppharmachologic effect
The antibiotic is a long-acting broad-spectrum tetracycline. It acts bacteriostatically, suppresses protein synthesis in the microbial cell by interacting with the 30S ribosomal subunit.
Active against gram-positive and gram-negative aerobic and anaerobic bacteria: Streptococcus spp., Staphylococcus spp., Klebsiella spp., Enterobacter spp. (including Enterobacter aerugenes), Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum, Listeria monocytogenes, Rickettsia spp. (including Rickettsia prowazekii), Escherichia coli, Shigella spp., Campylobacter fetus, Vibrio cholerae, Yersinia spp. (including Yersinia pestis), Brucella spp., Francisella tularensis, Bacillus anthracis, Bartonella bacilliformis, Pasteurella multocida, Borrelia recurrentis, Clostridium spp. (except Clostridium difficile), Actinomyces spp., Fusobacterium fusiforme, Calymmatobacterium granulomatosis, Propionibacterium acnes, Treponema spp., Typhus exanthematicus; some protozoa: Entamoeba spp., Plasmodium falciparum.
Usually, not active regarding Acinetobacter spp., Proteus spp., Pseudomonas spp., Serratia spp., Providencia spp., Enterococcus spp.
The possibility of acquired resistance to doxycycline in a number of pathogens, which is often cross-linked within a group, should be taken into account (i.e., strains resistant to doxycycline will simultaneously be resistant to the entire group of tetracyclines).
Pharmacokinetics
Suction
Absorption is fast and high (100%). Food intake has a slight effect on the absorption of the drug, which has no clinical significance.
Cmax of doxycycline in blood plasma (2.6-3 μg/ml) is achieved 2 hours after taking 200 mg; after 24 hours, the concentration of the active substance in blood plasma decreases to 1.5 μg/ml.
After taking 200 mg on the first day of treatment and 100 mg/day on subsequent days, the concentration of doxycycline in the blood plasma is 1.5-3 mcg/ml.
Distribution
Doxycycline reversibly binds to plasma proteins (80-90%), penetrates well into tissues, poorly into the cerebrospinal fluid (10-20% of the concentration in the blood plasma), however, the concentration of doxycycline in the cerebrospinal fluid increases with inflammation of the spinal membrane.
V d - 1.58 l/kg. 30-45 minutes after oral administration, doxycycline is found in therapeutic concentrations in the liver, kidneys, lungs, spleen, bones, teeth, prostate gland, eye tissue, pleural and ascitic fluids, bile, synovial exudate, exudate of the maxillary and frontal sinuses, in gingival sulcus fluids.
With normal liver function, the level of the drug in bile is 5-10 times higher than in plasma.
In saliva, 5-27% of the concentration of doxycycline in blood plasma is determined.
Doxycycline crosses the placental barrier and is secreted into breast milk in small quantities.
Accumulates in dentin and bone tissue.
Metabolism
Only a small portion of doxycycline is metabolized.
Removal
T1/2 after a single oral dose is 16-18 hours, after repeated doses - 22-23 hours.
Approximately 40% of the dose taken is excreted in a biologically active form by tubular secretion in the kidneys, 20-40% is excreted through the intestines in the form of inactive forms (chelates).
Pharmacokinetics in special clinical situations
T1/2 of doxycycline in patients with impaired renal function does not change, because its excretion through the intestines increases.
Hemodialysis and peritoneal dialysis do not affect the concentration of doxycycline in blood plasma.
Indications for use of the drug
Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:
- respiratory tract infections (including pharyngitis, acute bronchitis, exacerbation of chronic obstructive pulmonary disease, tracheitis, bronchopneumonia, lobar pneumonia, community-acquired pneumonia, lung abscess, pleural empyema);
— infections of the ENT organs (including otitis media, sinusitis, tonsillitis);
- infections of the genitourinary system (cystitis, pyelonephritis, bacterial prostatitis, urethritis, urethrocystitis, urogenital mycoplasmosis, acute orchiepididymitis; endometritis, endocervicitis and salpingoophoritis /as part of combination therapy/);
- sexually transmitted infections (urogenital chlamydia, syphilis in patients with penicillin intolerance, uncomplicated gonorrhea /as an alternative therapy/, granuloma inguinale, lymphogranuloma venereum);
- infections of the gastrointestinal tract and biliary tract (cholera, yersiniosis, cholecystitis, cholangitis, gastroenterocolitis, bacillary and amoebic dysentery, travelers' diarrhea);
- infections of the skin and soft tissues (including wound infections after animal bites), severe acne (as part of combination therapy);
— other diseases (yaws, legionellosis, chlamydia of various localizations / including prostatitis and proctitis/, rickettsiosis, Q fever, Rocky Mountain spotted fever, typhus / including typhus, tick-borne relapsing/, Lyme disease / stage I - erythema migrans/, tularemia, plague, actinomycosis, malaria, leptospirosis, psittacosis, psittacosis, anthrax /including pulmonary form/, bartonellosis, granulocytic ehrlichiosis, whooping cough, brucellosis);
- infectious eye diseases, as part of combination therapy - trachoma;
- osteomyelitis;
- sepsis;
— subacute septic endocarditis;
- peritonitis.
Prevention of postoperative purulent complications and malaria caused by Plasmodium falciparum during short-term travel (less than 4 months) to areas where strains resistant to chloroquine and/or pyrimethamine-sulfadoxine are common.
Dosage regimen
It is preferable to take the drug with food. The tablets are dissolved in a small amount of water (about 20 ml) to obtain a suspension. The tablets can also be swallowed whole, split into pieces, or chewed with water. Usually the duration of treatment is 5-10 days.
Adults and children over 8 years old weighing more than 50 kg on the first day of treatment, 200 mg/day is prescribed in 1 or 2 doses, on subsequent days of treatment - 100 mg/day in 1 dose. When severe infections prescribed 200 mg/day during the entire treatment period.
For children aged 8-12 years weighing less than 50 kg the average daily dose is 4 mg/kg on the first day, then 2 mg/kg/day (in 1-2 doses). In cases severe infections the drug is prescribed at a dose of 4 mg/kg daily throughout treatment.
For infection caused by Streptococcus pyogenes, the duration of treatment is at least 10 days.
At uncomplicated gonorrhea(except anorectal infections in men) adults prescribe 100 mg 2 times a day until complete cure (on average within 7 days), or prescribe 600 mg for one day - 300 mg in 2 doses (the second dose 1 hour after the first).
At primary syphilis prescribed 100 mg 2 times a day for 14 days, with secondary syphilis- 100 mg 2 times/day for 28 days.
At uncomplicated urogenital infections caused by Chlamydia trachomatis, cervicitis, non-gonococcal urethritis caused by Ureaplasma urealiticum, prescribed 100 mg 2 times a day for 7 days.
At acne Prescribed 100 mg/day, course of treatment is 6-12 weeks.
For malaria prevention prescribed 100 mg 1 time/day 1-2 days before the trip, then daily during the trip and for 4 weeks after returning; children over 8 years old- 2 mg/kg 1 time/day.
For prevention of traveler's diarrhea- 200 mg on the first day of the trip in 1 or 2 doses, then 100 mg 1 time / day during the entire stay in the region (no more than 3 weeks).
For treatment of leptospirosis- 100 mg orally 2 times a day for 7 days; For prevention of leptospirosis- 200 mg 1 time/week during stay in a disadvantaged area and 200 mg - at the end of the trip.
WITH to prevent infections during medical abortion Prescribe 100 mg 1 hour before and 200 mg after the intervention.
Maximum daily doses for adults- up to 300 mg/day or up to 600 mg/day for 5 days with severe gonococcal infections. For children over 8 years old weighing more than 50 kg - up to 200 mg, for children 8-12 years old weighing less than 50 kg- 4 mg/kg daily throughout treatment.
At renal (creatinine clearance less than 60 ml/min) and/or liver failure a reduction in the daily dose of doxycycline is required, since this results in a gradual accumulation of it in the body (risk of hepatotoxicity).
Side effect
From the digestive system: anorexia, nausea, vomiting, dysphagia, diarrhea, enterocolitis, pseudomembranous colitis, liver damage (during long-term use or in patients with renal or hepatic insufficiency).
Dermatological reactions: photosensitivity.
Allergic reactions: urticaria, maculopapular and erythematous rash, angioedema, anaphylactic reactions, pericarditis, exacerbation of systemic lupus erythematosus, exfoliative dermatitis.
From the hematopoietic system: hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia, decreased prothrombin activity.
From the endocrine system: In patients receiving long-term doxycycline, reversible dark brown discoloration of the thyroid tissue is possible.
From the side of the central nervous system: benign increase in intracranial pressure (anorexia, vomiting, headache, papilledema), vestibular disorders (dizziness or unsteadiness).
From the urinary system: increase in residual urea nitrogen (due to the anti-anabolic effect).
From the musculoskeletal system: doxycycline slows down osteogenesis, disrupts the normal development of teeth in children (irreversibly changes the color of teeth, enamel hypoplasia develops).
Others: candidiasis (glossitis, stomatitis, proctitis, vaginitis) as manifestations of superinfection.
Contraindications to the use of the drug
- severe dysfunction of the liver and/or kidneys;
- porphyria;
- pregnancy;
- lactation period (breastfeeding);
- children under 8 years of age;
- hypersensitivity to tetracycline antibiotics.
Use of the drug during pregnancy and lactation
Unidox Solutab ® is contraindicated for use during pregnancy.
The drug is contraindicated for use during lactation (breastfeeding). Doxycycline is excreted in breast milk.
Use for liver dysfunction
Contraindicated in cases of severe liver dysfunction.
For patients with impaired liver function, Unidox Solutab ® is prescribed only if treatment with other drugs is impossible.
At liver dysfunction it is necessary to reduce the dose of the drug.
Use for renal impairment
Contraindicated in cases of severe renal impairment.
special instructions
There is a possibility of cross-resistance and hypersensitivity with other tetracycline drugs.
Tetracyclines may increase prothrombin time; the use of tetracyclines in patients with coagulopathies should be carefully monitored.
The anti-anabolic effect of tetracyclines can lead to an increase in the level of residual urea nitrogen in the blood. As a rule, this is not significant for patients with normal renal function. However, in patients with renal failure, an increase in azotemia may occur. The use of tetracyclines in patients with impaired renal function requires medical supervision.
With long-term use of the drug, periodic monitoring of laboratory blood parameters, liver and kidney function is required.
Due to the possible development of photodermatitis, it is necessary to limit insolation during treatment and for 4-5 days after it.
Long-term use of the drug can cause dysbacteriosis and, as a result, the development of hypovitaminosis (especially B vitamins).
To prevent dyspeptic symptoms, it is recommended to take the drug with meals.
Impact on the ability to drive vehicles and operate machinery
The specific effects on the ability to drive a car and operate machinery have not been studied.
Overdose
Symptoms: increased adverse reactions caused by liver damage - vomiting, fever, jaundice, azotemia, increased transaminase levels, increased prothrombin time.
Treatment: immediately after taking large doses, gastric lavage, drinking plenty of fluids, and, if necessary, inducing vomiting are recommended. Take activated carbon and osmotic laxatives. Hemodialysis and peritoneal dialysis are not recommended due to low efficiency.
Drug interactions
Due to the suppression of intestinal microflora by doxycycline, the prothrombin index decreases, which requires dose adjustment of indirect anticoagulants.
When doxycilline is combined with bactericidal antibiotics that disrupt cell wall synthesis (penicillins, cephalosporins), the effectiveness of the latter is reduced, which should be taken into account when treating meningitis and tonsillopharyngitis caused by Streptococcus pyogenes.
Doxycycline reduces the reliability of contraception and increases the frequency of acyclic bleeding when taking estrogen-containing hormonal contraceptives.
Ethanol, barbiturates, rifampicin, carbamazepine, phenytoin, accelerating the metabolism of doxycycline, reduce its concentration in the blood plasma.
The simultaneous use of doxycycline and retinol increases intracranial pressure.
Conditions for dispensing from pharmacies
The drug is available with a prescription.
Storage conditions and periods
The drug should be stored out of the reach of children at a temperature of 15° to 25°C. Shelf life - 5 years.
